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Background
The present study analyzes the renal activity of the NO-
cGMP pathway in and the effect of the specific soluble
guanylate cyclase (sGC) stimulator Bay 41-2272 and
phosphodiesterases (PDEs) inhibitor pentoxifylline
(PTX) on a progressive model of anti-thy1-induced
chronic glomerulosclerosis (cGS).
Methods
cGS was induced by injection of anti-thy1 antibody into
uni-nephrectomized rats. One week after disease induc-
tion, animals were randomly assigned to: cGS, cGS+Bay
41-2272 (10 mg/kg body weight/d) or cGS+PTX (50 mg/
kg body weight/d). In week 16, animals were scarified and
materials analyzed.
Results
Compared to normal controls, sGC mRNA expression
(alpha1 sGC +260% and beta1 sGC +310%) and NO-
stimulated cGMP production (+270%) were up-regulated
in the tubulointerstitium of the untreated cGS animals,
while its activity was depressed in glomeruli (-50%). As
compared to untreated the cGS group, Bay 41-2272 treat-
ment significantly enhanced glomerular and tubulointer-
stitial NO-cGMP (+92% and +88%) signaling. This went
along with markedly reduced glomerular and tubulointer-
stitial macrophage infiltration (-42% and -50%), number
of proliferating cells (-31% and -30%), matrix protein
expression (TGF-β protein -36% and -50%) and accumu-
lation (histological matrix score -47% and -42%) as well
as improved kidney function (plasma creatinine -57%). In
contrast, PTX therapy only moderately, but not signifi-
cantly affected the above parameters.
Conclusions
Glomerular and tubulointerstitial sGC activity were dis-
cordantly altered in anti-thy1-induced chronic glomerulo-
sclerosis. Stimulation of sGC signaling by Bay 41-2272
limited the progressive course towards tubulointerstitial
fibrosis and impaired renal function, whereas the PDEs
inhibitor PTX did not significantly increase renal cGMP
levels and thereby had no effects on kidney fibrosis. The
results suggest that enhancing kidney cGMP levels by sGC
stimulation represents a novel effective anti-fibrotic
approach in progressive renal disease.
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